Cargando…

Development of a Novel Targeted Metabolomic LC-QqQ-MS Method in Allergic Inflammation

The transition from mild to severe allergic phenotypes is still poorly understood and there is an urgent need of incorporating new therapies, accompanied by personalized diagnosis approaches. This work presents the development of a novel targeted metabolomic methodology for the analysis of 36 metabo...

Descripción completa

Detalles Bibliográficos
Autores principales: Obeso, David, Contreras, Nuria, Dolores-Hernández, Mariana, Carrillo, Teresa, Barbas, Coral, Escribese, María M., Villaseñor, Alma, Barber, Domingo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319984/
https://www.ncbi.nlm.nih.gov/pubmed/35888716
http://dx.doi.org/10.3390/metabo12070592
_version_ 1784755683127721984
author Obeso, David
Contreras, Nuria
Dolores-Hernández, Mariana
Carrillo, Teresa
Barbas, Coral
Escribese, María M.
Villaseñor, Alma
Barber, Domingo
author_facet Obeso, David
Contreras, Nuria
Dolores-Hernández, Mariana
Carrillo, Teresa
Barbas, Coral
Escribese, María M.
Villaseñor, Alma
Barber, Domingo
author_sort Obeso, David
collection PubMed
description The transition from mild to severe allergic phenotypes is still poorly understood and there is an urgent need of incorporating new therapies, accompanied by personalized diagnosis approaches. This work presents the development of a novel targeted metabolomic methodology for the analysis of 36 metabolites related to allergic inflammation, including mostly sphingolipids, lysophospholipids, amino acids, and those of energy metabolism previously identified in non-targeted studies. The methodology consisted of two complementary chromatography methods, HILIC and reversed-phase. These were developed using liquid chromatography, coupled to triple quadrupole mass spectrometry (LC-QqQ-MS) in dynamic multiple reaction monitoring (dMRM) acquisition mode and were validated using ICH guidelines. Serum samples from two clinical models of allergic asthma patients were used for method application, which were as follows: (1) corticosteroid-controlled (ICS, n = 6) versus uncontrolled (UC, n = 4) patients, and immunotherapy-controlled (IT, n = 23) versus biologicals-controlled (BIO, n = 12) patients. The results showed significant differences mainly in lysophospholipids using univariate analyses in both models. Multivariate analysis for model 1 was able to distinguish both groups, while for model 2, the results showed the correct classification of all BIO samples within their group. Thus, this methodology can be of great importance for further understanding the role of these metabolites in allergic diseases as potential biomarkers for disease severity and for predicting patient treatment response.
format Online
Article
Text
id pubmed-9319984
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93199842022-07-27 Development of a Novel Targeted Metabolomic LC-QqQ-MS Method in Allergic Inflammation Obeso, David Contreras, Nuria Dolores-Hernández, Mariana Carrillo, Teresa Barbas, Coral Escribese, María M. Villaseñor, Alma Barber, Domingo Metabolites Article The transition from mild to severe allergic phenotypes is still poorly understood and there is an urgent need of incorporating new therapies, accompanied by personalized diagnosis approaches. This work presents the development of a novel targeted metabolomic methodology for the analysis of 36 metabolites related to allergic inflammation, including mostly sphingolipids, lysophospholipids, amino acids, and those of energy metabolism previously identified in non-targeted studies. The methodology consisted of two complementary chromatography methods, HILIC and reversed-phase. These were developed using liquid chromatography, coupled to triple quadrupole mass spectrometry (LC-QqQ-MS) in dynamic multiple reaction monitoring (dMRM) acquisition mode and were validated using ICH guidelines. Serum samples from two clinical models of allergic asthma patients were used for method application, which were as follows: (1) corticosteroid-controlled (ICS, n = 6) versus uncontrolled (UC, n = 4) patients, and immunotherapy-controlled (IT, n = 23) versus biologicals-controlled (BIO, n = 12) patients. The results showed significant differences mainly in lysophospholipids using univariate analyses in both models. Multivariate analysis for model 1 was able to distinguish both groups, while for model 2, the results showed the correct classification of all BIO samples within their group. Thus, this methodology can be of great importance for further understanding the role of these metabolites in allergic diseases as potential biomarkers for disease severity and for predicting patient treatment response. MDPI 2022-06-25 /pmc/articles/PMC9319984/ /pubmed/35888716 http://dx.doi.org/10.3390/metabo12070592 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Obeso, David
Contreras, Nuria
Dolores-Hernández, Mariana
Carrillo, Teresa
Barbas, Coral
Escribese, María M.
Villaseñor, Alma
Barber, Domingo
Development of a Novel Targeted Metabolomic LC-QqQ-MS Method in Allergic Inflammation
title Development of a Novel Targeted Metabolomic LC-QqQ-MS Method in Allergic Inflammation
title_full Development of a Novel Targeted Metabolomic LC-QqQ-MS Method in Allergic Inflammation
title_fullStr Development of a Novel Targeted Metabolomic LC-QqQ-MS Method in Allergic Inflammation
title_full_unstemmed Development of a Novel Targeted Metabolomic LC-QqQ-MS Method in Allergic Inflammation
title_short Development of a Novel Targeted Metabolomic LC-QqQ-MS Method in Allergic Inflammation
title_sort development of a novel targeted metabolomic lc-qqq-ms method in allergic inflammation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319984/
https://www.ncbi.nlm.nih.gov/pubmed/35888716
http://dx.doi.org/10.3390/metabo12070592
work_keys_str_mv AT obesodavid developmentofanoveltargetedmetabolomiclcqqqmsmethodinallergicinflammation
AT contrerasnuria developmentofanoveltargetedmetabolomiclcqqqmsmethodinallergicinflammation
AT doloreshernandezmariana developmentofanoveltargetedmetabolomiclcqqqmsmethodinallergicinflammation
AT carrilloteresa developmentofanoveltargetedmetabolomiclcqqqmsmethodinallergicinflammation
AT barbascoral developmentofanoveltargetedmetabolomiclcqqqmsmethodinallergicinflammation
AT escribesemariam developmentofanoveltargetedmetabolomiclcqqqmsmethodinallergicinflammation
AT villasenoralma developmentofanoveltargetedmetabolomiclcqqqmsmethodinallergicinflammation
AT barberdomingo developmentofanoveltargetedmetabolomiclcqqqmsmethodinallergicinflammation